Engaging all stakeholders in the process of establishing a global MI service is key to its overall success. Each ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

The 2nd Hit ID Summit is your go-to hub for drug hunters looking to crack through targets and uncover quality leads. Join 60+ ...

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a ...

Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial ...

Hopes have risen for a new treatment option for a rare and severe form of childhood epilepsy, Dravet syndrome, after Biogen and Stoke Therapeutics reported new data for their recently partnered ...

Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem ...